Latest Human Genome Sciences Stories
ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
Human Genome Sciences has completed enrollment and initial dosing of patients in a randomized Phase II trial of HGS-ETR1 in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced financial results and key developments for the quarter ended June 30, 2008.
ROCKVILLE, Md., July 24 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced that David P. Southwell has been appointed to the HGS Board of Directors. He will also serve as a member of the Company's Audit Committee. Until recently, Mr.
BOSTON (Reuters) - Biotechnology company Human Genome Science Inc. said on Wednesday that it plans shortly to seek approval from U.S. regulators to run a late-stage clinical trial of its drug to treat systemic lupus erythematosus, a chronic, life-threatening disease. If the U.S.
WASHINGTON (Reuters) - Human Genome Sciences Inc. plans to announce a deal with the U.S. government on Monday to provide as many as 100,000 doses of an experimental anthrax drug, the Washington Post reported.
ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
- The act of sweetening by admixture of some saccharine substance.